Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6024 studies found for:    vaccines
Show Display Options
Rank Status Study
1 Completed Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
Condition: Plague Vaccine
Interventions: Biological: rF1V vaccine (with Adjuvant);   Biological: rF1V vaccine (without Adjuvant)
2 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
3 Completed School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities
Conditions: Immunizations;   Vaccination;   Influenza;   School Health
Interventions: Behavioral: School based flu vaccine: Low intensity;   Behavioral: School based flu vaccine: High intensity
4 Completed
Has Results
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
Condition: Influenza
Interventions: Biological: Cell culture-derived influenza subunit vaccine (cTIV);   Biological: Egg derived influenza subunit vaccine (eTIV_f)
5 Completed
Has Results
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine;   Biological: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
6 Completed
Has Results
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
7 Completed
Has Results
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Condition: Influenza
Interventions: Biological: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
8 Completed Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
Condition: Botulism Vaccine
Interventions: Biological: Placebo (USP sterile saline for injection);   Biological: rBV A/B-40 vaccine
9 Completed
Has Results
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Conditions: Pertussis;   Whooping Cough;   Tetanus;   Lockjaw;   Diphtheria
Interventions: Biological: Acellular pertussis vaccine;   Biological: Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed);   Biological: Licensed TdaP booster vaccine;   Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany);   Other: Saline solution
10 Completed Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
Condition: Prophylaxis of Avian Influenza Vaccine
Intervention: Biological: Fluad H5N1 Pandemic Influenza Vaccine
11 Completed
Has Results
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Condition: Pandemic Influenza Disease
Interventions: Biological: Placebo;   Biological: Trivalent influenza virus vaccine (TIV);   Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1);   Biological: Adjuvanted trivalent influenza vaccine (aTIV)
12 Completed
Has Results
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Condition: Prevention of Meningococcal Disease
Interventions: Biological: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation);   Biological: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation);   Biological: MenACWY PS (MenACWY-CRM, polysaccharide vaccine);   Biological: HBV (Hepatitis B vaccine);   Biological: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197);   Biological: MMR (Measles, Mumps and Rubella vaccine);   Biological: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine);   Biological: Menjugate (Men C conjugated vaccine)
13 Completed
Has Results
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Condition: Invasive Meningococcal Disease
Interventions: Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.;   Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.;   Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
14 Completed
Has Results
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
Condition: Streptococcal Infections
Interventions: Biological: Group B Streptococcus Trivalent Vaccine - 20/20/20 μg;   Other: Saline solution;   Biological: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg;   Biological: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg;   Biological: Group B Streptococcus Trivalent Vaccine - 5/5/5 μg;   Other: saline solution
15 Completed
Has Results
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine;   Biological: Licensed comparator
16 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
17 Completed
Has Results
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
Conditions: Seasonal Influenza;   Vaccine
Interventions: Biological: Cell-derived influenza vaccine;   Biological: Egg-derived influenza vaccine
18 Completed
Has Results
Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
Condition: Influenza
Interventions: Drug: AS03;   Biological: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
19 Completed Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine-Admixture 1;   Biological: TetraVax-DV Vaccine-Admixture 2;   Biological: TetraVax-DV Vaccine-Admixture 3;   Biological: TetraVax-DV Vaccine-Admixture 4;   Biological: Placebo;   Biological: TetraVax-DV Vaccine-Admixture 5
20 Completed Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
Condition: Influenza
Interventions: Biological: Fluzone® Quadrivalent vaccine, 2014-2015 formulation;   Biological: Fluzone I®ntradermal vaccine, 2014-2015 formulation;   Biological: Fluzone High Dose vaccine, 2014-2015 formulation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years